Novartis licenses tuberculosis drugs to TB Alliance

08/20/2014 | Genetic Engineering & Biotechnology News

Novartis has signed a licensing agreement with the Global Alliance for TB Drug Development for compounds against tuberculosis. Novartis will fully transfer its tuberculosis research and development program to the TB Alliance, which will finance and handle ongoing research, development, approval and distribution of the compounds. One of these is NITD304, which blocks a protein associated with the TB bacterium's survival.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA